6/21/2013 7:43:46 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
Sanofi's new bowel cancer drug Zaltrap is not worth using on Britain's state health service given its high price, the country's healthcare cost watchdog said on Friday. The National Institute for Health and Clinical Excellence (NICE) said the medicine was clinically effective but it could not be considered a cost-effective use of National Health Service resources - even though Sanofi offered a discount. The draft decision, which is now open to consultation, will be a disappointment for the French drugmaker and its U.S. biotech partner Regeneron Pharmaceuticals. It is not a complete surprise, however, since NICE previously turned down a similar medicine, Avastin, made by Roche.
Help employers find you! Check out all the jobs and post your resume.
comments powered by